Pacific Biosciences Of California (PACB) Total Current Liabilities (2010 - 2026)

Pacific Biosciences Of California's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $65.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 1.87% year-over-year to $65.4 million; the TTM figure through Mar 2026 stood at $65.4 million (down 1.87% YoY), while the FY2025 annual figure was $72.8 million, up 9.85% from the prior year.
• Total Current Liabilities was $65.4 million for Q1 2026 at Pacific Biosciences Of California, down from $72.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $271.4 million in Q2 2023 to a low of $59.8 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $112.5 million across 5 years, with a median of $73.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 335.46% in 2023, then slumped 72.54% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $263.3 million in 2022, then tumbled by 63.91% to $95.0 million in 2023, then sank by 30.23% to $66.3 million in 2024, then gained by 9.85% to $72.8 million in 2025, then declined by 10.26% to $65.4 million in 2026.
• The last three Total Current Liabilities figures came in at $65.4 million (Q1 2026), $72.8 million (Q4 2025), and $63.2 million (Q3 2025), per Business Quant data.